A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.
Giuseppe Visani,Pietro Maria Stefani,Saveria Capria,Lara Malerba,Piero Galieni,Francesco Gaudio,Giorgina Specchia,Giovanna Meloni,Filippo Gherlinzoni,Roberta Gonella,Marco Gobbi,Armando Santoro,Felicetto Ferrara,Marco B. L. Rocchi,Enrique M. Ocio,Maria Dolores Caballero,Federica Loscocco,Alessandro Isidori +17 more
TL;DR: High-dose chemotherapy followed by autologous stem cell rescue has become the standard of care for patients with relapsed, chemosensitive aggressive non-Hodgkin lymphoma (NHL).
Journal ArticleDOI
Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials
Maurizio Infante,Stefano Sestini,Carlotta Galeone,Alfonso Marchianò,Fabio Romano Lutman,Enzo Angeli,Giuseppina Calareso,Giuseppe Pelosi,Gabriella Sozzi,Mario Silva,Nicola Sverzellati,Silvio Cavuto,Carlo La Vecchia,Armando Santoro,Marco Alloisio,Ugo Pastorino +15 more
TL;DR: A patient-level pooled analysis of two Italian randomized controlled trials shows a nonsignificant 11% reduction in overall mortality in individuals undergoing LDCT screening as compared with the control arm.
Journal ArticleDOI
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Lorenza Rimassa,Tiziana Pressiani,Corrado Boni,Carlo Carnaghi,Elena Rota Caremoli,Stefano Fagiuoli,Paolo Foa,Stefania Salvagni,Enrico Cortesi,Maria Chiara Tronconi,Nicola Personeni,Silvia Bozzarelli,Maria Banzi,Silvia Fanello,Fabio Romano Lutman,Laura Giordano,Armando Santoro +16 more
TL;DR: Escalated-dose sorafenib in patients with advanced HCC who progressed while on sorafinib, failed to provide any clinical benefit and still remains an open issue to be explored in appropriate clinical trials.
Journal ArticleDOI
Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells?
Silvia Della Bella,Stefania Nicola,I Timofeeva,Maria Luisa Villa,Armando Santoro,Anna C. Berardi +5 more
TL;DR: It is shown that IL-16 added to a basal cocktail comprised of granulocyte-macrophage colony-stimulating factor, IL-4, Flt-3 ligand, and tumor necrosis factor alpha (TNF-alpha) does induce the CD34(+) hematopoietic cells to proliferate in vitro and to differentiate into phenotypically and functionally mature DCs.
Journal ArticleDOI
Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients
Marta Scorsetti,Antonella Fogliata,S. Castiglioni,Caterina Bressi,Mario Bignardi,Piera Navarria,Pietro Mancosu,Luca Cozzi,S. Pentimalli,Filippo Alongi,Armando Santoro +10 more
TL;DR: These preliminary results stated that volumetric modulated arc therapy in locally advanced head and neck cancers is feasible and effective, with acceptable toxicities.